NCT07306273 2025-12-29
IRE Combined With the Dual-Function Antibody PD-1/CTLA-4 for the Treatment of LAPC Following Failure of First-Line AG Therapy
Ruijin Hospital
Phase 2 Recruiting
Clinical Trials
6 trialsNCT03630640 2024-07-31
NIVOLEP
Assistance Publique - Hôpitaux de Paris
Phase 2 Completed
NCT05609656 2024-06-03
ELI
Zealand University Hospital
Phase 2 Terminated
NCT05435053 2023-09-15
CHECKPOINT
Zealand University Hospital
Phase 2 Terminated
NCT02082782 2022-12-20
COLDFIRE-2
Amsterdam UMC, location VUmc
Phase 2 Completed
NCT04835402 2022-03-09
EPIC-1
Aalborg University Hospital
Phase 2 Unknown